Sunde Yilmaz Susluer

Sunde Yilmaz Susluer

Auto-generated profile, based on publicly available information

Sunde Yilmaz Susluer

EGE ÜNİVERSİTESİ, EGE TIP FAKÜLTESİ

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
CACigir Biray Avci
Cigir Biray Avci
EHEce Harman
Ece Harman
YDYavuz Dodurga
Yavuz Dodurga
SSSunde Yilmaz Susluer
Sunde Yilmaz Susluer
CGCumhur Gunduz
Cumhur Gunduz
Prostate cancer is the most commonly diagnosed cancer in males in many populations. Metformin is the most widely used anti-diabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anti-cancer drug. Metformin inhibits the proliferation of a range of cancer cells including prostate, colon, breast, ovarian, and glioma lines. MicroRNAs (miRNAs) are a class of small, non- coding, single-stranded RNAs that downregulate gene expression. We aimed to evaluate the effects of metformin treatment on changes in miRNA expression in PC-3 cells, and possible associations with biological behaviour. Average cell viability and cytotoxic effects of metformin were investigated at 24 hour intervals for three days using the xCELLigence system. The IC50 dose of metformin in the PC-3 cells was found to be 5 mM. RNA samples were used for analysis using custom multi-species microarrays containing 1209 probes covering 1221 human mature microRNAs present in miRBase 16.0 database. Among the human miRNAs investigated by the arrays, 10 miRNAs were up-regulated and 12 miRNAs were down-regulated in the metformin-treated group as compared to the control group. In conclusion, expression changes in miRNAs of miR-146a, miR-100, miR-425, miR-193a-3p and, miR-106b in metformin-treated cells may be important. This study may emphasize a new role of metformin on the regulation of miRNAs in prostate cancer.

1 September 2016 in Gene
Verified
Journal Article
Closed access
TBTugce Balci
Tugce Balci
SSSunde Yilmaz Susluer
Sunde Yilmaz Susluer
CKCagla Kayabasi
Cagla Kayabasi
BYBesra Ozmen Yelken
Besra Ozmen Yelken
CACigir Biray Avci
Cigir Biray Avci
CGCumhur Gunduz
Cumhur Gunduz

26 August 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
FSFatma Sogutlu
Fatma Sogutlu
CKCagla Kayabasi
Cagla Kayabasi
BYBesra Ozmen Yelken
Besra Ozmen Yelken
AAAycan Asik
Aycan Asik
RGRoya Gasimli
Roya Gasimli
CGCumhur Gunduz
Cumhur Gunduz

1 January 2022 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
UCUgur C.YIlmaz
Ugur C.YIlmaz
BBBakiye Goker Bagca
Bakiye Goker Bagca
EKEmin Karaca
Emin Karaca
ADAsude Durmaz
Asude Durmaz
BDBurak Durmaz
Burak Durmaz
OCOzgur Cogulu
Ozgur Cogulu
Background: Grade IV gliomas are classified as glioblastoma (GBM), which is the most malignant brain cancer type. Various genetic and epigenetic mechanisms play a role in the initiation and progression of GBM. MicroRNAs (miRNAs) are small, non-coding RNA molecules that belong to the main epigenetic regulatory RNA class that plays different roles in either physiological or pathological conditions, including GBM pathogenesis regulating expression levels of the target genes. Brain Cancer Stem Cells (BCSCs) are responsible for poor prognosis, including therapy resistance and relapse. Epigenetic regulation mediated by miRNAs is also a critical component of BCSC selfrenewal and differentiation properties. Propolis is a resinous substance collected by honey bees from various plant sources. The flavonoid content of propolis varies depending on the collection region and the extraction method. Although there are studies that include the effects of different originated-propolis on the miRNA expression levels of the glioblastoma cells, the impact on the BCSCs has not been studied yet. Objective: This study aims to evaluate the effects of propolis obtained from Aydın, a city in western Turkey, on miRNA expression levels of BCSCs and GBM cells. Methods: Aydin propolis was dissolved in 60% ethanol, and after evaporation, distilled water was added to prepare the propolis stock solution. The flavonoids content of the Aydin propolis was determined by MS Q-TOF analysis. Commercially obtained U87MG and BCSCs were used as in-vitro brain cancer models. Cytotoxic and apoptotic effects of Aydın propolis were determined via WST-1 assay and Annexin V test, respectively. The miRNA expression profile was investigated using the real-time qRT-PCR method. The fold changes were calculated by the2-ΔΔCt method. The miRNA-mRNA-pathway interactions, including significantly altered miRNAs, were determined using different bioinformatics tools and databases. Results: Quercetin 3-methyl ether was the main component of the Aydin propolis. Aydin propolis did not show significant cytotoxic and apoptotic effects on both GBM and BCSCs up to 2mg/ml concentration. Aydin propolis treatment decreased the expression of nine miRNAs in the U87MG and five miRNAs in the BCSCs. Moreover, ten miRNAs have upregulated from 2.22 to 10.56 folds in propolis treated GBM cells compared to the control group significantly (p<0.05). In the study, the potential roles of two new miRNAs, whose regulations in glioma were not previously defined, were identified. One of them was miR-30d-5p, a novel potential oncomiR in GBM, which was 2.46 folds downregulated in Aydin propolis treated GBM cells. The other one is miR-335-5p, which is a potential tumor suppressor miR in GBM, that was 5.66 folds upregulated in Aydin propolis treated GBM cells. FOXO pathway, its upstream and downstream regulators, and critically neuronal developmental regulators, NOTCH and WNT pathways, were determined as the most deregulated pathways in Aydin propolis treated cells. Conclusion: The determination of the anti-cancer effect of Aydın propolis on the miRNA expression of GBM, especially on cancer stem cells, may contribute to the elucidation of brain cancer genetics by supporting further analyses.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BDBurak Durmaz
Burak Durmaz
BBBakiye Goker Bagca
Bakiye Goker Bagca
OCOzgur Cogulu
Ozgur Cogulu
SSSunde Yilmaz Susluer
Sunde Yilmaz Susluer
AAAraz Alpay
Araz Alpay
CGCumhur Gunduz
Cumhur Gunduz
Prednisolone has been used frequently in the treatment of acute lymphoblastic leukemia. However, to overcome the challenges of the treatment, the development of additional therapies is of great importance. Small, non‐protein‐coding RNAs, namely, microRNAs (miRNAs), are critical epigenetic regulators with physiological and pathological importance. This study is aimed at determining the effects of miR‐146a, miR‐155, and miR‐181a inhibition with their corresponding anti‐miRs on both leukemic and healthy cells, individually and with prednisolone. Leukemic (SUP‐B15) and healthy B‐lymphocyte (NCI‐BL 2171) cell lines were used in this study. A total of 12 experimental groups included individual and combinational silenced ALL‐associated miRNAs (hsa‐miR‐155, hsa‐miR‐146a, and hsa‐miR‐181a) and their combination with prednisolone. Cytotoxicity, proliferation, cell cycle, and apoptosis analyses were performed by using WST‐1, trypan blue, APC‐BrdU, Annexin V, and JC‐1 methods in each study group, respectively. To control the effectiveness of anti‐miR transfection and prednisolone application, miRNA expression analysis was performed from all groups. Anti‐miR application was effective on the viability, proliferation, cell cycle, and apoptosis of leukemia cells, and this effect was increased with prednisolone administration. In addition, this activity was found to be very low on healthy cells. In conclusion, anti‐miR applications may have the potential for clinical use of adjuvant to or as an alternative to conventional therapies for childhood acute lymphoblastic leukemia.

12 July 2023 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
RGRoya Gasimli
Roya Gasimli
CKCagla Kayabasi
Cagla Kayabasi
BYBesra Ozmen Yelken
Besra Ozmen Yelken
AAAycan Asik
Aycan Asik
FSFatma Sogutlu
Fatma Sogutlu
CGCumhur Gunduz
Cumhur Gunduz
PI3K/Akt/mTOR pathway activation causes relapse and resistance after radiotherapy in breast cancer (BC). We aimed to radiosensitize BC cell lines to IR by PKI-402, a dual PI3K/mTOR inhibitor. We performed cytotoxicity, clonogenicity, hanging drop, apoptosis and DSB detection, and phosphorylation of 16 essential proteins involved in the PI3K/mTOR pathway. Our findings showed that PKI-402 has cytotoxic efficiency in all cell lines. Clonogenic assay results showed that PKI-402 plus IR inhibited the colony formation ability of MCF-7 and BCSC cell lines. Results showed that PKI-402 plus IR causes more apoptotic cell death than IR alone in the MCF-7 cells but did not cause significant changes in the MDA-MB-231. γ-H2AX levels were increased in MDA-MB-231 in PKI-402 plus IR groups, whereas we did not observe any apoptotic and γ-H2AX induction in BCSCs and MCF-10A cells in all treatment groups. Some pivotal phosphorylated proteins of the PI3K/AKT pathway decreased, several proteins increased and others did not change. In conclusion, if the combined use of PKI-402 with radiation is supported by in vivo studies, it can contribute to the treatment options and the course of the disease.